journal article·2018-02

Effect of Retro‐Inverso Isomer of Bradykinin on Size‐Dependent Penetration of Blood–Brain Tumor Barrier

Bingxia Su, Ruifeng Wang, Zuoxu Xie, Huitong Ruan, Jichen Li, Cao Xie, Weiyue Lu, Jing Wang, Dongli Wang, Min Liu

Small· Volume 14· Issue 7
Publisher page

Abstract

Abstract Retro‐inverso bradykinin (RI‐BK) has better metabolic stability and higher affinity for the BK type 2 (B2) receptor, compared with bradykinin. At low doses, RI‐BK can selectively enhance the permeability of the blood–brain tumor barrier (BBTB) without harming normal brain tissue. In this study, gold nanoparticles (GNPs) of size ranging from 5 to 90 nm are synthesized to assess the optimal size of nanocarriers that achieves maximum brain accumulation after the treatment of RI‐BK. The ability of the GNPs to cross the BBTB is tested in a rat C6 glioma tumor model. The results of inductively coupled plasma–mass spectrometry and transmission electron microscopy indicate that GNPs with size of 70 nm achieve maximum permeability to the glioma. The present study supports the conclusion that RI‐BK can enhance the permeability of BBTB and provides fundamental information for further development of nanomedicines or nanoprobes for glioma therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Smart Drug Delivery Ministry of Education Department of Pharmaceutics School of Pharmacy Fudan University 826 Zhangheng Road Shanghai 201203 P. R. China

Funding

National Natural Science Foundation of China

References (33)

Show source-provided references
1. Perkins A. · Am. Fam. Physician · 2016 · 93 · 211
2. 10.1124/jpet.301.3.83810.1124/jpet.301.3.838 ↗
3. 10.1016/j.drudis.2006.10.01310.1016/j.drudis.2006.10.013 ↗
4. 10.1016/S1359-6446(00)01583-X10.1016/S1359-6446(00)01583-X ↗
5. 10.1016/j.brainresrev.2010.05.00310.1016/j.brainresrev.2010.05.003 ↗
6. 10.1016/j.addr.2011.11.01010.1016/j.addr.2011.11.010 ↗
7. 10.1517/17425247.2012.68272610.1517/17425247.2012.682726 ↗
8. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
9. Leeblundberg L. M. · Pharmacol. Rev. · 2005 · 57 · 2710.1124/pr.57.1.2 ↗
10. 10.1016/j.canlet.2015.08.01010.1016/j.canlet.2015.08.010 ↗
11. 10.1016/j.colsurfb.2014.12.04110.1016/j.colsurfb.2014.12.041 ↗
12. 10.1002/adma.20140155410.1002/adma.201401554 ↗
13. 10.1021/mp300594710.1021/mp3005947 ↗
14. 10.1002/adhm.20120008410.1002/adhm.201200084 ↗
15. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
16. 10.1021/ja208433810.1021/ja2084338 ↗
17. 10.1021/nl900031y10.1021/nl900031y ↗
18. 10.1038/nnano.2008.3010.1038/nnano.2008.30 ↗
19. 10.1021/cr03069810.1021/cr030698 ↗
20. 10.1158/1535-7163.MCT-08-001610.1158/1535-7163.MCT-08-0016 ↗
21. 10.1016/j.biomaterials.2007.12.03710.1016/j.biomaterials.2007.12.037 ↗
22. 10.1021/ja907069u10.1021/ja907069u ↗
23. 10.1002/ange.20130946410.1002/ange.201309464 ↗
24. 10.1002/anie.20130946410.1002/anie.201309464 ↗
25. 10.1021/acs.langmuir.6b0128910.1021/acs.langmuir.6b01289 ↗
26. 10.1007/s11060-010-0124-x10.1007/s11060-010-0124-x ↗
27. 10.1080/10717549926711010.1080/107175499267110 ↗
28. 10.1080/0268869050030555510.1080/02688690500305555 ↗
29. 10.1016/j.tins.2012.05.00110.1016/j.tins.2012.05.001 ↗
30. 10.1016/S0306-4522(02)00374-310.1016/S0306-4522(02)00374-3 ↗
31. 10.1016/S0006-8993(98)00498-310.1016/S0006-8993(98)00498-3 ↗
32. 10.1016/0006-8993(95)01143-910.1016/0006-8993(95)01143-9 ↗
33. 10.1007/s11095-010-0265-910.1007/s11095-010-0265-9 ↗